Predictors of Treatment Initiation with Tumor Necrosis Factor-α Inhibitors in Patients with Rheumatoid Arthritis

BACKGROUND: Introduction of biologic disease-modifying antirheumatic drugs (DMARDs) has revolutionized treatment in patients with rheumatoid arthritis (RA). However, due to substantially higher costs of biologics compared with nonbiologics, patients with less insurance generosity may have difficulty...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Rishi J., Rao, Jaya K., Hansen, Richard A., Fang, Gang, Maciejewski, Matthew L., Farley, Joel F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441023/
https://www.ncbi.nlm.nih.gov/pubmed/25351972
http://dx.doi.org/10.18553/jmcp.2014.20.11.1110

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10441023/
https://www.ncbi.nlm.nih.gov/pubmed/25351972
http://dx.doi.org/10.18553/jmcp.2014.20.11.1110

Ejemplares similares